Peer-reviewed veterinary case report
Dogs with intestinal T-cell lymphoma showing unusual CD20 marker
By Noland, Erica L & Kiupel, Matti·Published in Veterinary pathology·2018·1 Department of Pathobiology and Diagnostic Investigation, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Coexpression of CD3 and CD20 in Canine Enteropathy-Associated T-cell Lymphoma.
- Species:
- dog
Plain-English summary
Three dogs diagnosed with a type of intestinal cancer called enteropathy-associated T-cell lymphoma (EATL) were reported. These dogs, aged between 3 and 12 years, showed symptoms like weight loss, lack of appetite, diarrhea, and vomiting. The survival time varied greatly, with some dogs living as little as 20 days while others survived for over a year and a half. Accurate diagnosis is crucial for determining the best treatment, as different types of lymphomas respond differently to chemotherapy.
People also search for: dog vomiting and weight loss · canine lymphoma treatment · dog diarrhea and inappetence
Abstract
The majority of primary intestinal lymphomas in dogs are T-cell lymphomas, with enteropathy-associated T-cell lymphoma (EATL) large cell type (type 1) being the most common. While most T-cell lymphomas express the T-cell marker CD3, there is increasing evidence that some human and canine T-cell lymphomas coexpress the B-cell marker CD20. We describe 3 cases of CD3, CD20, Pax5EATL type 1 in dogs. All 3 cases had clonal rearrangement of T-cell receptor gamma. Initial clinical signs included weight loss, inappetence, diarrhea, and/or vomiting. The mean age was 9 years (range 3-12). Survival was highly variable ranging from 20 days to longer than 1.6 years. Considering the different chemotherapeutic response of T-cell versus B-cell lymphomas, accurate diagnosis of lymphomas coexpressing CD3 and CD20 as EATL type 1 based on histologic features and clonality results is important. Regardless, the clinical and/or prognostic significance of neoplastic T cells expressing CD20 is unclear.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/29343197/